Valencia biomedical company, Mann Kind Corp., appointed Michael E. Castagna Chief Commercial Officer, the company announced Monday.
The appointment takes effect immediately.
On another note, the company’s Chief Operating Officer, Juergen A. Martens, is resigning March 18. No reason was given for his departure.
Castagna, MannKind’s new CCO, will lead commercialization efforts for the company’s diabetes treatment inhaler, Afrezza, reporting to CEO Matthew Pfeffer. He will also serve on the firm’s executive leadership team.
"His extensive pharma background, including driving sales and marketing for so many new and relaunched products, will be invaluable as we prepare to reintroduce Afrezza to the market in the coming months,"Pfeffer said.
Castagna was formerly with Amgen Inc. in Thousand Oaks. He has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries.
While at Amgen, he spent over three years working with a portfolio of nine biosimilar drugs.
Prior to Amgen, Castagna helped launch rheumatoid arthritis drugs for Bristol-Myers Squibb.
Overall, MannKind reported that he has over 20 years of experience in healthcare, pharmaceutical, biotech and specialty pharmacy industries.
"I am excited to be joining MannKind at this critical intersection as we transform our future,” Castagna said. “I am enthusiastic about the commercial opportunity for Afrezza and the potential it has to help adults with diabetes manage this difficult disease."

